Scholar Rock Holding (SRRK) Current Deferred Revenue (2017 - 2021)
Scholar Rock Holding's quarterly Current Deferred Revenue came in at $33.2 million in Q4 2021, up 76.41% year-on-year from $18.8 million in Q4 2020, and down 10.87% quarter-over-quarter from $37.2 million in Q3 2021.
Scholar Rock Holding has reported Current Deferred Revenue for 5 years, with the latest figure at $33.2 million in Q4 2021.
- For the quarter ending Q4 2021, Current Deferred Revenue rose 76.41% year-over-year to $33.2 million; the trailing twelve-month figure through Dec 2021 stood at $33.2 million (up 76.41% YoY), and the FY2021 full-year result was $33.2 million, up 76.41% from the prior year.
- Current Deferred Revenue for Q4 2021 stood at $33.2 million, down from $37.2 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $47.3 million in Q1 2021, with the low at $228000.0 in Q4 2017.
- Average Current Deferred Revenue over 5 years is $24.5 million, with a median of $20.6 million recorded in 2019.
- Year-over-year, Current Deferred Revenue jumped 8763.6% in 2018 and slumped 35.84% in 2020.
- Tracing SRRK's Current Deferred Revenue over 5 years: stood at $228000.0 in 2017, then jumped by 8763.6% to $20.2 million in 2018, then climbed by 3.53% to $20.9 million in 2019, then fell by 10.07% to $18.8 million in 2020, then jumped by 76.41% to $33.2 million in 2021.
- The last three Current Deferred Revenue figures came in at $33.2 million (Q4 2021), $37.2 million (Q3 2021), and $42.7 million (Q2 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 33.19 Mn |
| Sep 30, 2021 | 37.24 Mn |
| Jun 30, 2021 | 42.71 Mn |
| Mar 31, 2021 | 47.30 Mn |
| Dec 31, 2020 | 18.82 Mn |
| Sep 30, 2020 | 16.71 Mn |
| Jun 30, 2020 | 20.36 Mn |
| Mar 31, 2020 | 16.27 Mn |
| Dec 31, 2019 | 20.92 Mn |
| Sep 30, 2019 | 20.25 Mn |
| Jun 30, 2019 | 23.52 Mn |
| Mar 31, 2019 | 25.36 Mn |
| Dec 31, 2018 | 20.21 Mn |
| Dec 31, 2017 | 228,000.00 |